Table 4 Comparison of immune modulatory... | American Society of Hematology

Table 4

Comparison of immune modulatory derivatives in patients with AL

Regimen, source	No.	No prior Rx, %	2 or more organs, %	Cardiac, %	Heme response, %	Organ response, %	Median f/u, mo	Grade 3-4 AEs, %
Dex
Palladini et al⁷	23	43	48	39	13	30	39	NR
Gertz et al⁸	25	100	NR	68	40	12	18	NR
Gertz et al⁹	19	0	NR	63	53	16	27	NR
Dex-IFN
Dhodapkar et al¹⁰	87	84	71	50	27	17	41	46/53‡
Thal/Dex
Palladini et al²⁷	31	42	61	38	48	26	32	65
Thal
Seldin et al²⁸*	16	6	31	25	25	0	NR	50
Dispenzieri et al²⁹*	12	58	67	42	0	11	2.3§	58
Dispenzieri et al³⁰†	18	28	50	67	0	11	5.6§	75
Len with or without Dex
Current study	22	43	57	65	43	26	17	83

Regimen, source	No.	No prior Rx, %	2 or more organs, %	Cardiac, %	Heme response, %	Organ response, %	Median f/u, mo	Grade 3-4 AEs, %
Dex
Palladini et al⁷	23	43	48	39	13	30	39	NR
Gertz et al⁸	25	100	NR	68	40	12	18	NR
Gertz et al⁹	19	0	NR	63	53	16	27	NR
Dex-IFN
Dhodapkar et al¹⁰	87	84	71	50	27	17	41	46/53‡
Thal/Dex
Palladini et al²⁷	31	42	61	38	48	26	32	65
Thal
Seldin et al²⁸*	16	6	31	25	25	0	NR	50
Dispenzieri et al²⁹*	12	58	67	42	0	11	2.3§	58
Dispenzieri et al³⁰†	18	28	50	67	0	11	5.6§	75
Len with or without Dex
Current study	22	43	57	65	43	26	17	83

Rx indicates treatment; Cardiac, cardiac involvement; f/u, follow-up; mo, months; AEs, adverse events; Dex, dexamethasone; IFN, interferon; Thal, thalidomide; and Len, lenalidomide.

200-800 mg.

†

50-200 mg.

‡

Induction phase/maintenance phase.

Median time on the treatment.

View Large

This Feature Is Available To Subscribers Only